In Ireland, an average of ten women are diagnosed with breast cancer every day when a cancer charity unveiled a landmark research project into new personalized treatment programmes.
reakthrough Cancer Research (BCR) will work with leading Irish medical schools and the world-renowned Johns Hopkins Cancer Center in the US to investigate personalized treatment programs designed to maximize treatment regimen efficacy and reduce treatment-related side effects for Irish patients.
BCR researcher Dr. Maeve Hennessy said the treatment program aims to transform the entire patient experience.
“Our goal is to improve the treatment decision for an individual patient with breast cancer, meaning that certain patients could avoid toxic and futile therapies, while other patients could be directed to a more intensive approach to maximize their cancer outcome and improve survival rates.” “, she said.
The new research is being conducted with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, the Translational Breast Cancer Consortium, Cancer Trials Ireland and the Royal College of Surgeons Ireland (RCSI).
By improving treatment regimens, the team hopes to improve cancer outcomes and overall survival rates.
Research will focus on treating early-stage breast cancer.
Each year more than 3,500 women are diagnosed with breast cancer in Ireland – approximately ten women are diagnosed with the disease every day.
A key goal of research into personalized treatment plans is to reduce unnecessary toxic and ineffective therapies – thereby offering a more intensive treatment approach.
The research of dr. Hennessy will continue under the direction of Prof Roisin Connolly, a consultant medical oncologist at Cork University Hospital (CUH).
The core element of the research will focus on using biomarkers to measure response and resistance in two niche subsets of early breast cancer.
“This would allow for optimization of treatment decisions for an individual patient, meaning that certain patients could avoid toxic and futile therapies, while other patients could be referred to a more intensive approach to maximize their outcome.” hennessy
Prof Connolly said research is key to improving outcomes and overall survival rates.
“The research of Dr. Hennessy will include ongoing collaborative projects with US breast cancer teams and the development of new projects with Irish collaborators,” she said.
“Ultimately, we hope to bring new and better treatment regimens and diagnostics to patients who have been diagnosed with cancer. The results of this study will help advance personalized breast cancer treatment and will also inform important future research areas. We want to find better treatment options for patients and, at diagnosis, determine which course of treatment is most appropriate for that person.”
BCR chief executive Orla Dolan said it is an extremely exciting research program.
“The research project of Dr. Hennessy is extremely important and could benefit hundreds of breast cancer patients at home and abroad,” she said.
BCR works closely with practicing researchers and clinicians across Ireland, so research aims to find new treatment options for a range of cancers, including those that are incurable or have a poor prognosis.
Over the past 20 years, BCR has helped advance eight novel treatments into clinical trials and the organization has five more in the pipeline.
https://www.independent.ie/irish-news/landmark-research-project-unveiled-by-charity-will-focus-on-early-stage-breast-cancer-treatment-41988659.html Pioneering research project presented by charity focuses on treatment of early breast cancer